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Introduction {#cam41222-sec-0001}
============

In the hierarchy of epidemiological evidence on causes of cancer, longitudinal studies (either nested case--control or case--cohort studies) are second only to randomized trial evidence [1](#cam41222-bib-0001){ref-type="ref"}, [2](#cam41222-bib-0002){ref-type="ref"}. The Finnish Maternity Cohort (FMC) was established in 1983 to provide a resource for such studies. All women in Finland are at their 12th week of pregnancy offered screening for congenital infections (hepatitis B, HIV, and syphilis). The residual serum samples are stored in the FMC [3](#cam41222-bib-0003){ref-type="ref"}. There is a separate legal basis for the collection and scientific use of FMC (The law of the National Institute for Health and Welfare 668/2008). Since 2001, a nationwide informed consent system based on the opt‐out principle with negligible drop out has been in operation.

An example of pioneering cancer research based on the FMC are longitudinal studies documenting that exposure to human papillomavirus (HPV) types 16 and 18 causes an excess risk for later development of both cervical, other anogenital and oropharyngeal cancers [4](#cam41222-bib-0004){ref-type="ref"}, [5](#cam41222-bib-0005){ref-type="ref"}, [6](#cam41222-bib-0006){ref-type="ref"}. FMC\'s serial samples have been useful for disentangling the temporal order of events in carcinogenesis, for example, antagonistic interaction of different HPV types [7](#cam41222-bib-0007){ref-type="ref"}, and disclosing smoking as an independent risk factor of cervical cancer [8](#cam41222-bib-0008){ref-type="ref"}. The prediagnostic serial samples also enable studies on the sensitivity and specificity of biomarkers for future cancer diagnosis and screening [9](#cam41222-bib-0009){ref-type="ref"}. High‐quality data on the gestational date of the sample collection enable studies on hormones and cancer [10](#cam41222-bib-0010){ref-type="ref"}. The FMC is positioned as an international Open Access resource. Linkage of personal identifiers with the nationwide, population‐based Finnish Cancer Registry and other population‐based health and trial registries establishes a unique study base for longitudinal studies [11](#cam41222-bib-0011){ref-type="ref"}.

Material and Methods {#cam41222-sec-0002}
====================

At the end of 2016 the FMC comprised 2.0 million serum samples from about 1 million women. As the congenital screening is repeated on each pregnancy, serial samples are available for about 50% of the women. Moreover, there are approximately 100,000 pairs of mothers and daughters, who both have donated sera to the FMC for scientific research.

We estimated the numbers of incident cancer cases in the FMC (Table [1](#cam41222-tbl-0001){ref-type="table-wrap"}). Cancer incidence in the FMC is similar to that in the general female population for all cancer types [11](#cam41222-bib-0011){ref-type="ref"}, with the exception of endometrial cancer which is decreased (43%) due to protection from pregnancy. Thus, it was possible to estimate the number of cancer cases by multiplying the person‐years generated by women in FMC by the end of year 2014 with cancer incidence rate in the Finnish female population in each 5‐year age category ([www.cancerregistry.fi](http://www.cancerregistry.fi)).

###### 

Estimated[a](#cam41222-note-0002){ref-type="fn"} numbers of incident invasive cancer cases in the Finnish Maternity Cohort 1983--2014

  Primary site                        ICD‐10 code                               After first sample (*N* = 953,000)   After second sample (*N* = 604,000)   After third sample (*N* = 240,000)
  ----------------------------------- ----------------------------------------- ------------------------------------ ------------------------------------- ------------------------------------
  All sites                           C00--96, D32--33, D42--43, D45--47, D76   39,700                               19,900                                6800
  Mouth, pharynx                      C00--14                                   490                                  220                                   85
  Lip                                 C00                                       10                                   5                                     1
  Tongue                              C02                                       110                                  50                                    5
  Mouth, other                        C03--06                                   110                                  50                                    15
  Salivary glands                     C07--08                                   110                                  50                                    20
  Pharynx                             C01, C09--14                              130                                  55                                    20
  Digestive organs                    C15--26                                   3900                                 1900                                  700
  Esophagus                           C15                                       65                                   30                                    10
  Stomach                             C16                                       550                                  280                                   95
  Small intestine                     C17                                       110                                  55                                    20
  Colon                               C18                                       1400                                 700                                   250
  Rectum, rectosigmoid, anus          C19--20                                   790                                  380                                   130
  Liver                               C22                                       135                                  50                                    20
  Gallbladder, bile ducts             C23--24                                   140                                  60                                    20
  Pancreas                            C25                                       530                                  230                                   85
  Other digestive organs              C26                                       30                                   10                                    0
  Respiratory organs                  C30--39                                   1050                                 420                                   130
  Nose, sinuses                       C30--31                                   35                                   15                                    5
  Larynx, epiglottis                  C32                                       15                                   5                                     2
  Lung, trachea                       C33--34                                   980                                  350                                   110
  Mediastinum, pleura                 C38                                       10                                   8                                     4
  Bone                                C40--41                                   90                                   40                                    10
  Melanoma of the skin                C43                                       2200                                 1200                                  430
  Skin, nonmelanoma                   C44                                       400                                  180                                   60
  Mesothelioma                        C45                                       20                                   9                                     3
  Autonomic nervous system            C47                                       10                                   4                                     0
  Soft tissues                        C48--49                                   280                                  140                                   60
  Breast                              C50                                       18,400                               9200                                  3000
  Female genital organs               C51--58                                   3800                                 1700                                  550
  Cervix uteri                        C53                                       1130                                 630                                   260
  Corpus uteri                        C54                                       1100                                 400                                   130
  Uterus, other                       C55, C58                                  20                                   5                                     1
  Ovary                               C56                                       1100                                 500                                   150
  Other female genital                C51--52, C57                              280                                  110                                   25
  Placenta                                                                      15                                   4                                     2
  Urinary organs                      C64--68                                   900                                  400                                   160
  Kidney                              C64                                       620                                  290                                   120
  Bladder and urinary tract           C65--68                                   270                                  110                                   40
  Eye                                 C69                                       70                                   30                                    10
  Brain, central nervous system       C70--72, D32--33, D42--43                 2500                                 1400                                  500
  Thyroid gland                       C73                                       2300                                 1300                                  520
  Other endocrine glands              C74--75                                   50                                   20                                    5
  Ill defined or unknown              C76, C80                                  300                                  130                                   40
  Lymphoid and hematopoietic tissue   C81--96, D45--47, D76                     2600                                 1300                                  430
  Hodgkin lymphoma                    C81                                       350                                  180                                   55
  Non‐Hodgkin lymphoma                C82--86, C96, D76                         1200                                 600                                   200
  Myeloma                             C90                                       220                                  100                                   25
  Leukemia                            C91--95                                   600                                  300                                   90

96% of the Finnish pregnant women between 1983 and 2016 have consented to participate in the FMC. As the women can withdraw consent at will the numbers should be considered as estimates.
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Results {#cam41222-sec-0003}
=======

There are approximately 40,000 prospectively occurring cases of cancer within 17.2 million person‐years of follow‐up up to 2014. During the first 5 years after pregnancy, the number of new cancer cases is moderate but increases when the women become older. Breast cancer comprised almost half of all incident invasive cancer cases identified (18,400 cases, Table [1](#cam41222-tbl-0001){ref-type="table-wrap"}).

The next 10 most common cancer types were as follows: thyroid cancer (2300 cases), melanoma (2200 cases), colorectal cancers (2190 cases), lymphomas (1550 cases), cervical cancer (1130 cases), endometrial cancer (1100 cases), ovarian cancer (1100 cases), lung cancer (980 cases), kidney cancer (620 cases), and leukemia (600 cases). Noninvasive cancers include 10,000 cases of in situ cervical cancer, 7400 cases of basal cell carcinomas, and 1500 cases of in situ breast carcinomas.

The number of childhood cancer cases in the offspring of the FMC donors (4000 cases) is sizeable (Table [2](#cam41222-tbl-0002){ref-type="table-wrap"}). Especially, the numbers of childhood leukemias and lymphomas (altogether more than 1600 cases) are high (Table [2](#cam41222-tbl-0002){ref-type="table-wrap"}).

###### 

Estimated[a](#cam41222-note-0003){ref-type="fn"} numbers of incident invasive cancer cases in the offspring of the Finnish Maternity Cohort participants (FMC) 1983--2014

  Cancer type                     ICD10                                     Boys   Girls   All                                                       
  ------------------------------- ----------------------------------------- ------ ------- ----- ------ ------ ----- ----- ------ ------ ----- ----- ------
  All sites                       C00--96, D32--33, D42--43, D45--47, D76   1180   535     445   2160   1020   420   410   1850   2200   955   855   4010
  Mouth, pharynx                  C00--14                                   \<5    \<5     10    10     0      \<5   5     10     \<5    5     15    20
  Digestive organs                C15--26                                   20     10      25    60     15     10    45    70     35     25    70    130
  Respiratory organs              C30--39                                   10     \<5     5     15     10     5     0     15     15     10    5     30
  Female genital organs           C51--58                                                               10     5     20    35     10     5     20    35
  Male genital organs             C60--63                                   30     5       5     40                               30     5     5     40
  Urinary organs                  C64--68                                   110    20      5     135    105    20    5     130    220    40    10    270
  Melanoma of the skin            C43                                       5      5       15    20     0      5     10    15     5      10    20    35
  Skin, nonmelanoma               C44                                       0      5       5     10     5      0     5     5      5      5     5     15
  Eye                             C69                                       55     5       5     65     45     5     5     50     105    5     5     115
  Thyroid gland                   C73                                       5      5       5     15     0      5     15    20     5      10    20    35
  Other endocrine glands          C74--75                                   90     10      10    110    90     5     5     100    180    15    15    210
  Bone                            C40--41                                   5      15      25    45     15     10    25    50     15     20    55    90
  Soft tissues                    C48--49                                   40     20      15    75     45     20    10    75     90     35    30    155
  Ill defined or unknown          C76, C80                                  5      5       5     15     5      5     5     15     10     10    5     25
  Autonomic nervous system        C47                                       40     5       5     50     40     5     5     50     80     5     5     90
  Brain, CNS                      C70--72, D32--33, 42--43                  265    185     140   590    195    145   115   455    460    330   260   1050
  Lymphoid, hematopoetic tissue   C81--96, D45--47, D76                     500    235     175   910    445    175   155   770    940    410   325   1675

96% of all Finnish pregnant women between 1983 and 2014 have consented to participate in the FMC. As the women can later withdraw consent at will the numbers should be considered as estimates.
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Discussion {#cam41222-sec-0004}
==========

Cancer incidence in the FMC is similar to that in the general female population for all cancer types [11](#cam41222-bib-0011){ref-type="ref"}, with the exception of endometrial cancer which is decreased (43%) due to protection from pregnancy. With only 20 women opting out in 2017, the population‐based nature of FMC remains virtually intact.

In addition to longitudinal studies on cancer etiology and screening studies, the resource is also potentially useful for studies on genetic cancer risk. However, the first trimester serum samples contain measurable amounts of fetal DNA, which needs to be controlled for in genetic studies [12](#cam41222-bib-0012){ref-type="ref"}. Because the FMC is nationwide and contains samples from 94% of all Finnish pregnant women [11](#cam41222-bib-0011){ref-type="ref"}, very large‐scale over‐generation studies can be designed by linking the identities of the mothers to their offspring and/or relatives [13](#cam41222-bib-0013){ref-type="ref"}. Due to the long history of the FMC, prospects for studying congenital causes of cancer in the offspring of the women in FMC are also good.

Ongoing FMC projects include studies of the possible role of the same microbiome, that is, similar serological signature for mothers and daughters with the same cancer for the same types of *Chlamydia trachomatis* [14](#cam41222-bib-0014){ref-type="ref"}, HPV [7](#cam41222-bib-0007){ref-type="ref"}, *Helicobacter pylori,* or *Streptococcus galolyticus* in familial cervical, colorectal, and stomach cancers, respectively.

The FMC sample collection can also support clinical trials and surveillance purposes, including cancer control. For example, we are currently comparing the long‐term stability of antibody responses induced by either quadrivalent or bivalent vaccines against HPV among women who participated as adolescents in large randomized albeit population‐based trials of these vaccines [15](#cam41222-bib-0015){ref-type="ref"}. By linking the clinical trial files to the FMC files, it has been possible to identify serum samples collected up to 14 years postvaccination. Evaluation of vaccine‐induced antibody response in yet‐to‐be‐identified breakthrough cases makes search for correlates of protective immunity feasible.

This cohort profile describes the basic characteristics of the FMC and provides some examples of its potential use. The FMC is also a role model in strict safe guarding of integrity and compliance with data protection laws. While linkages of course need to be performed with identifiable data, once the samples are retrieved they are pseudonymized and it is not possible to link the research data to an identifiable individual. To promote the use of the FMC as an international resource for epidemiological cancer research, an international nonprofit company (ESIS EEIG) specializing in assisting international researchers with the data and samples they need has been founded and is available to facilitate the formal and logistic process to obtain access to the samples and data that international cancer research may need ([www.esis.fi](http://www.esis.fi)).
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